Kimia Biosciences Ratios

Kimia Biosciences Ltd Ratios

The Kimia Biosciences Ltd Ratios page provides a complete fundamental analysis of Kimia Biosciences Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Kimia Biosciences Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Kimia Biosciences Ltd (NSE: , BSE: 530313) is currently trading at ₹33.56, with a market capitalization of ₹154.81Cr. As a major player in the Health technology sector and Pharmaceuticals: major industry, Kimia Biosciences Ltd remains a key stock for fundamental analysis using Kimia Biosciences Ltd Ratios.

Kimia Biosciences Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Kimia Biosciences Ltd P/E ratio currently stands at 20.92, making it one of the most tracked metrics in Kimia Biosciences Ltd Ratios.

Historically, the Kimia Biosciences Ltd P/E ratio has shown strong fluctuations:

• 2025: 20.92
• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 35.17

The rising Kimia Biosciences Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Kimia Biosciences Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 20.18.

Historical P/B trend:

• 2025: 20.18
• 2024: 796.60
• 2023: 28.15
• 2022: 11.95

Kimia Biosciences Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Kimia Biosciences Ltd P/S ratio currently stands at 1.70, an important part of Kimia Biosciences Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2025: 1.70
• 2024: 2.53
• 2023: 1.20
• 2022: 1.43

A stable or declining Kimia Biosciences Ltd P/S ratio indicates cautious market sentiment.

Kimia Biosciences Ltd Price to Cash Flow Ratio (P/CF)

The Kimia Biosciences Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 13.04.

Historical Kimia Biosciences Ltd Price to Cash Flow Ratio:

• 2025: 13.04
• 2024: 24.66
• 2023: 0
• 2022: 38.09
• 2021: 50.69

The declining Kimia Biosciences Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Kimia Biosciences Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Kimia Biosciences Ltd EV currently stands at ₹240Cr, representing the total company valuation including debt.

Historical EV trend:

• 2025: 240Cr
• 2024: 313Cr
• 2023: 206Cr
• 2022: 223Cr

Kimia Biosciences Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Kimia Biosciences Ltd EV/EBITDA ratio is currently 12.13, a key metric in Kimia Biosciences Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2025: 12.13
• 2024: 0
• 2023: 0
• 2022: 521.95

Higher Kimia Biosciences Ltd EV/EBITDA suggests premium valuation.

Kimia Biosciences Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Kimia Biosciences Ltd D/E ratio is currently 3.95, reflecting leverage and financial stability.

Historical D/E:

• 2025: 3.95
• 2024: 149.59
• 2023: 9.69
• 2022: 3.06

Higher D/E ratio indicates rising financial risk.

Return on Equity (ROE %)

The Kimia Biosciences Ltd ROE currently stands at 186.70%, showing profitability and capital efficiency.

Historical ROE:

• 2025: 186.70
• 2024: -183.25
• 2023: -91.91
• 2022: -22.22

Kimia Biosciences Ltd demonstrates strong profitability and efficient capital utilization.

Kimia Biosciences Ltd Ratios Analysis Summary

The Kimia Biosciences Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Kimia Biosciences Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Kimia Biosciences Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.